HIV Medicine最新文献

{"title":"HIV disease hospitalizations and factors associated with in-hospital mortality in Ecuador: A nationwide analysis from 2015 to 2023","authors":"German Josuet Lapo-Talledo,&nbsp;Ángel Luis Zamora Cevallos,&nbsp;Carlos Rafael Arteaga Reyes,&nbsp;José Daniel Sánchez Redrobán,&nbsp;Jhon Ernesto Delgado Pinargote,&nbsp;Ángela María Espinoza Guevara,&nbsp;Edgar Antonio Menéndez Cuadros","doi":"10.1111/hiv.70040","DOIUrl":"10.1111/hiv.70040","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objective</h3>\u0000 \u0000 <p>Human immunodeficiency virus (HIV) remains a significant public health concern worldwide, contributing to notable rates of hospitalization and mortality. This study aimed to analyse HIV disease hospitalization trends and factors associated with in-hospital mortality in Ecuador during 2015–2023.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Official national hospital discharge data were used. Hospitalization and in-hospital mortality rates were calculated. Multivariable logistic regression was performed to obtain adjusted odds ratios (aORs) and 95% confidence intervals (CIs) to identify factors associated with in-hospital mortality.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Totally 28 408 HIV disease hospitalizations were analysed; the majority were males 61.19% (<i>n</i> = 17 383). Average hospitalization rate was 18.48 per 100 000 inhabitants. In-hospital deaths accounted for 11.31% (<i>n</i> = 3214). Older age (≥40 years) was significantly associated with a higher likelihood of death, particularly in 60–69 years (aOR 1.78, 95% CI 1.49–2.13) and ≥70 years (aOR 1.79, 95% CI 1.36–2.34). Patients with HIV-related Pneumocystis jirovecii pneumonia (aOR 2.74, 95% CI 2.28–3.29) and multiple malignant neoplasms (aOR 4.30, 95% CI 1.66–11.15) had the highest mortality likelihood. Although a declining trend in mortality rates was observed throughout 2015–2023, there was an increase in mortality probabilities in 2021 which may be linked to healthcare disruptions during the COVID-19 pandemic, while subsequent decline in 2022 and 2023 suggests improvements in HIV care access.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>While HIV-related hospitalizations and mortality have declined in Ecuador, older patients and those with severe opportunistic infections or malignancies remain at higher risk. These findings underscore the need for early diagnosis, enhanced management of HIV-related complications and sustained antiretroviral therapy (ART) coverage, particularly during public health crises.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":"26 7","pages":"1108-1124"},"PeriodicalIF":2.8,"publicationDate":"2025-05-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144017635","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antiretroviral therapy use, self-reported adherence, and viral suppression among women living with HIV in Canada","authors":"Maysaloun Mokaddam,&nbsp;Nadine Kronfli,&nbsp;Nancy L. Sheehan,&nbsp;Araceli Gonzalez Reyes,&nbsp;Danièle Dubuc,&nbsp;Mona Loutfy,&nbsp;Angela Kaida,&nbsp;Alexandra de Pokomandy,&nbsp;the CHIWOS research team","doi":"10.1111/hiv.70034","DOIUrl":"10.1111/hiv.70034","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Traditionally, ≥95% adherence was recommended for viral suppression (VS). Newer antiretroviral therapy (ART) is now being increasingly prescribed and may be more forgiving of lower adherence. The lifelong nature of ART presents adherence challenges, particularly for women living with HIV. We aimed to describe ART use and examine the association between adherence and VS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>The Canadian HIV Women's Sexual and Reproductive Health Cohort, which included 1422 participants, was used. Data was collected three times, at 18-month intervals, between 2013 and 2018. A Sankey diagram illustrated longitudinal ART trends among participants who reported their ART use. Cross-sectional analysis using 2017–2018 data included participants who self-reported their regimen, ART adherence, and viral load. Utilizing logistic regression models, self-reported adherence (percentage of ART taken in the past month) and self-reported VS (most recent &lt;50 copies/mL) were investigated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among participants reporting ART use (<i>n</i> = 1187), integrase inhibitor use increased from 13.6% (<i>n</i> = 162) to 30.6% (<i>n</i> = 363), while other classes decreased. Among 617 participants assessed between 2017 and 2018, &lt;70% adherence levels (adjusted odds ratio [aOR]: 0.06, 95% confidence interval [CI]: 0.01–0.27), 70%–79% adherence (aOR: 0.29, 95% CI: 0.05–1.77) and 80%–89% (aOR: 0.21, 95% CI: 0.05–0.86) were associated with lower odds of reporting VS compared with ≥95% adherence, although statistically not significant for 70%–79% adherence. No difference was found for 90%–94% adherence (aOR: 1.04, 95% CI: 0.20–5.32) compared with ≥95%.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>Our findings suggest that ART adherence levels lower than 90% are associated with a lower likelihood of VS among women living with HIV.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":"26 7","pages":"1060-1073"},"PeriodicalIF":2.8,"publicationDate":"2025-05-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hiv.70034","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143997915","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Immune profiles and HIV reservoir in people switching to long-acting cabotegravir/rilpivirine: Findings from a real-life prospective study","authors":"Maria Mazzitelli,&nbsp;Maria Raffaella Petrara,&nbsp;Claudia Cozzolino,&nbsp;Lolita Sasset,&nbsp;Davide Leoni,&nbsp;Elena Ruffoni,&nbsp;Samuele Gardin,&nbsp;Beatrice Bragato,&nbsp;Angela Panese,&nbsp;Vincenzo Scaglione,&nbsp;Baldo Vincenzo,&nbsp;Anita De Rossi,&nbsp;Anna Maria Cattelan","doi":"10.1111/hiv.70030","DOIUrl":"10.1111/hiv.70030","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Data on the dynamics of HIV-DNA and immune profiles under treatment with long-acting cabotegravir and rilpivirine (LACR) are limited.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We prospectively enrolled people living with HIV who initiated LACR in our centre and assessed changes in HIV-DNA levels (measured by digital droplet PCR), as well as immune activated, senescent, exhausted, and regulatory T and B cells (analysed by flow cytometry), in peripheral blood mononuclear cells (PBMC) from baseline (T0) to 48 weeks of treatment (T5). Bivariate analyses, one-way repeated measures ANOVA and mixed ANOVA were conducted to assess differences in characteristics and biomarker changes over time between individuals switching to LACR from a dual (Group A) or triple (Group B) antiretroviral regimen.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 71 persons were included (77.5% males, median age of 48 years). Overall, HIV-DNA levels exhibited a slight non-significant decrease, whereas activated CD8 cells decreased significantly (<i>p</i> &lt; 0.001). Proportions of activated CD4 and regulatory T cells showed strong negative trends, but decreases did not reach statistical significance (<i>p</i> = 0.002 and 0.005). The dynamics of these markers within the two subgroups mirrored those of the entire cohort, with some differences. At baseline, Group A tended to exhibit higher levels of HIV-DNA (96 [31–160] vs. 41 [6–93] copies/10⁶ PBMC, <i>p</i> = 0.088), and activated CD4 (% activated CD4 cells: 2.3 [1–2.9] vs. 1 [0.7–2], <i>p</i> = 0.154) and CD8 cells (% activated CD8 cells: 4.9 [2.2–5.8] vs. 2.2 [1.2–3.5], <i>p</i> = 0.023) than Group B. Over the 48-week treatment period, HIV-DNA levels decreased slightly in both groups, remaining higher in Group A. At the end of the 48-week treatment period, the decrease of activated CD4 and CD8 cells was more pronounced in Group A than in Group B, ultimately reaching comparable levels between the two groups (% of activated CD4 cells: 0.9 [0.6–1.9] vs. 0.7 [0.6–1.1], <i>p</i> = 0.502): % of CD8 activated cells: (2 [1.3–2.5] vs. 1.6 [0.9–2.2], <i>p</i> = 0.278).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 <p>During the first year of treatment, LACR does not significantly impact the HIV reservoir. However, it may reduce immune activation, particularly in persons switching from a dual therapy regimen.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":"26 6","pages":"940-950"},"PeriodicalIF":2.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143981879","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of COVID-19 and factors associated with long COVID and COVID-19 vaccine uptake in people with HIV in the United Kingdom: Results from Positive Voices 2022","authors":"F. Nakagawa,&nbsp;R. Palich,&nbsp;M. Kall,&nbsp;J. Sewell,&nbsp;C. Smith,&nbsp;C. Kelly,&nbsp;H. Kitt,&nbsp;A. Pelchen-Matthews,&nbsp;A. Aghaizu,&nbsp;A. Sparrowhawk,&nbsp;N. Mackie,&nbsp;T. Djuretic,&nbsp;S. Schoeman,&nbsp;C. Humphreys,&nbsp;M. Lipman,&nbsp;F. C. Lampe,&nbsp;A. J. Rodger,&nbsp;the PV2022 Study Group","doi":"10.1111/hiv.70026","DOIUrl":"10.1111/hiv.70026","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>We assessed the impact of COVID-19, and the prevalence and factors associated with a history of COVID-19 infection, long COVID and incomplete COVID-19 vaccine uptake among people with HIV.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Positive Voices 2022 is a questionnaire study of people accessing HIV care in the United Kingdom (March 2022–April 2023). Logistic regression assessed factors associated with a history of COVID-19 (previous positive test), long COVID among those with a history of COVID-19 (ongoing symptoms, with COVID-19 onset &gt;3 months previously) and incomplete COVID-19 vaccine uptake (less than three doses of vaccine), adjusted for: age; gender; ethnicity; and year of HIV diagnosis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>In all, 4188 participants were included. Commonly reported negative impacts of the pandemic were on social contact (44% of participants), mental health (30%), healthcare access (26%) and financial security (25%). Overall, 2068 of 4188 (49.4%) participants had a history of COVID-19. Of these, 10.8% met criteria for long COVID, associated with female gender, unemployment, financial hardship, earlier HIV diagnosis date, diabetes diagnosis, asthma/chronic obstructive pulmonary disease diagnosis, obesity and symptoms of depression and anxiety. Overall, 95.8% reported having at least one vaccine dose, but 649 (15.7%) participants had incomplete vaccine uptake, associated with younger age, female gender, Black African ethnicity, lower education, financial hardship, unemployment, multioccupancy household, more recent HIV diagnosis, detectable HIV viral load and symptoms of depression and anxiety.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>About half of participants had a history of COVID-19, of whom 11% had persistent symptoms (long COVID). COVID-19 vaccine uptake was high, but incomplete uptake was apparent for 16% of participants and was more common among women, younger people, Black African individuals and those with socio-economic disadvantage.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":"26 6","pages":"923-939"},"PeriodicalIF":2.8,"publicationDate":"2025-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hiv.70026","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144012225","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cytomegalovirus serostatus among people with HIV, characterizing the prevalence, risk factors, and association with immune recovery","authors":"Joshua Quisias,&nbsp;M. John Gill,&nbsp;Sally B. Coburn,&nbsp;Hartmut B. Krentz,&nbsp;Brenda Beckthold,&nbsp;Kevin Fonseca,&nbsp;Michael D. Parkins,&nbsp;Raynell Lang","doi":"10.1111/hiv.70036","DOIUrl":"10.1111/hiv.70036","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Cytomegalovirus (CMV) infection is common among people with HIV (PWH), and may be associated with negative outcomes. We aimed to identify the seroprevalence of CMV between 01 January 1998 and 01 June 2022 among PWH accessing care at the Southern Alberta Clinic (SAC) and the associated risk factors. We also aimed to assess the impact of CMV seropositivity on CD4+ T-cells and CD4+/CD8+ ratio recovery among PWH who maintain HIV viral suppression.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Poisson regression models with robust variance estimated crude and adjusted prevalence ratios and 95% confidence intervals to identify risk factors for CMV seronegativity. Among PWH maintaining viral suppression, trends in the median CD4+ T-cell count and CD4+/CD8+ ratio were visualized, and continuous time-to-event Cox proportional hazard models estimated hazards ratios (aHR) for CD4+ cell count recovery to ≥500 cells/mm³ and CD4+/CD8+ ratio of &gt;1 at 10 years by CMV serostatus.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 3249 PWH, 2954 (91%) were CMV seropositive. CMV seronegativity was associated with younger ages, male sex, non-Hispanic white race and an education of ≥12 years. While CMV seronegativity did not affect CD4+ T-cell recovery following HIV viral suppression (aHR 1.15 [0.89–1.48]), it was associated with a greater likelihood of CD4+/CD8+ ratio normalization (aHR 2.38 [1.85–3.07]) at 10 years of follow-up.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>CMV is a common coinfection among PWH. We found that CMV positivity among PWH maintaining HIV viral suppression, while not associated with CD4+ T-cell recovery, was associated with a reduced CD4+/CD8+ ratio recovery. This suggests an association with chronic CMV infection-mediated immune activation and inflammation among PWH.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":"26 7","pages":"1074-1085"},"PeriodicalIF":2.8,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hiv.70036","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144005982","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Safety and effectiveness of switch to bictegravir/emtricitabine/tenofovir alafenamide following dual regimen therapy in people with HIV: Insights from the Icona cohort","authors":"Andrea De Vito,&nbsp;Alessandro Tavelli,&nbsp;Alessandro Cozzi-Lepri,&nbsp;Andrea Giacomelli,&nbsp;Roberto Rossotti,&nbsp;Giacomo Ponta,&nbsp;Nicoletta Bobbio,&nbsp;Alice Ianniello,&nbsp;Antonella Cingolani,&nbsp;Giordano Madeddu,&nbsp;Andrea Antinori,&nbsp;Antonella d'Arminio Monforte,&nbsp;ICONA Foundation Study Group","doi":"10.1111/hiv.70037","DOIUrl":"10.1111/hiv.70037","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>Most treatment switches are for simplification from three-drug (3DR) to dual regimens (2DR). However, a proportion of people with HIV may switch back to 3DR, like bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) after 2DR.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We included people with HIV enroled in the Icona cohort who switched to B/F/TAF after 2DR INSTI-based (3TC/DTG, RPV/DTG, RPV/CAB, or DOR + DTG). Virological rebound (VR), virological suppression (VS), and treatment discontinuation (TD) due to toxicity or failure were evaluated using Kaplan–Meier curves. Random intercept and slopes before and after the switch were used to evaluate the trajectories of triglycerides, cholesterol, CD4, and CD4/CD8. Viro-immunological analyses were stratified according to HIV-RNA at switch.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among the 3662 people with HIV who started a 2DR INSTI-based regimen, 71 (1.9%) switched to B/F/TAF; 60 had been followed up after the switch, for a median of 10.9 months (interquartile range: 3.6–24.7). Forty people with HIV switched with HIV-RNA &lt;50 copies/mL (uVL), 20 with HIV-RNA ≥50 copies/mL (dVL). Among the uVL group, one participant experienced VR (HIV-RNA: 99, 71 followed by 29 copies/mL). Among the dVL group, the 1-year cumulative probability of undetectable VL was 75% (95% confidence interval [CI] 57.6–95.1). Fourteen people with HIV interrupted B/F/TAF for simplification (50.0%), toxicity (28.6%), VR (14.2%), and patient's choice (7.1); the 1-year cumulative probability of TD for toxicity/failure was 10.7% (95% CI 14.5–24.5). We observed an increase in the CD4/CD8 ratio (+0.02 CD4/CD8/month, <i>p</i> = 0.026) only in the dVL group.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Switching from 2DR-INSTI to B/F/TAF is infrequent; this switch results in a low rate of toxicity and failure, along with a favourable immunovirological and lipid profile. CD4/CD8 gain is observed in those switching with detectable HIV-RNA.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":"26 6","pages":"970-977"},"PeriodicalIF":2.8,"publicationDate":"2025-04-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hiv.70037","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143981806","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Using an automated decision support tool to improve HIV prescribing: A feasibility study","authors":"Aidan T. Ireland,&nbsp;Jennifer Ward,&nbsp;Heather Dolby,&nbsp;Christopher Lawrence","doi":"10.1111/hiv.70028","DOIUrl":"10.1111/hiv.70028","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Objectives</h3>\u0000 \u0000 <p>The selection of antiretroviral therapy (ART) regimens for people living with HIV is complex and dependent on individual and clinician-perceived risk factors and preferences. The British HIV Association (BHIVA) advocates cost-effective prescribing and shared decision-making between patients and clinicians. We evaluated the acceptability and potential impact of a prototype multi-patient automated decision support tool (DST) for improving individualized, safe, and cost-effective prescribing.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We surveyed people living with HIV and clinicians regarding treatment preferences and the acceptability of a DST. We developed a DST to interpret electronic patient record data, using 2022 BHIVA guidelines to identify optimal ART switch options. This was applied to patients prescribed ART between June 2022 and May 2023 in the local HIV service, and potential cost savings were calculated.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among people living with HIV, 86.7% (144/166) respondents were open to switching to more cost-effective ART. While 94% (15/16) of clinician respondents prioritized lower-cost treatments where possible, only 38% (6/16) reported knowing about ART costs.</p>\u0000 \u0000 <p>Regimen switch options were identified for 274 of 503 people living with HIV meeting the inclusion criteria. Overall, potential cost savings of 28.4% of total ART spend (£26630.25 per month) were calculated if all possible switches to the most cost-effective option identified by the DST were made.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>A DST based on BHIVA recommendations and using routinely collected data may be acceptable to patients, useful to clinicians, and could provide significant cost savings. A substantial proportion of people living with HIV in our cohort were open to considering changing their ART based on cost effectiveness.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":"26 6","pages":"914-922"},"PeriodicalIF":2.8,"publicationDate":"2025-04-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/hiv.70028","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143993721","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Oral abstracts","authors":"","doi":"10.1111/hiv.70010","DOIUrl":"https://doi.org/10.1111/hiv.70010","url":null,"abstract":"","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":"26 S2","pages":"3-16"},"PeriodicalIF":2.8,"publicationDate":"2025-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143852904","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Poster abstracts","authors":"","doi":"10.1111/hiv.70013","DOIUrl":"https://doi.org/10.1111/hiv.70013","url":null,"abstract":"","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":"26 S2","pages":"17-137"},"PeriodicalIF":2.8,"publicationDate":"2025-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143852996","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"HCV incidence in people with HIV in southwest China: A retrospective cohort study (2004–2023)","authors":"Minyang Xiao,&nbsp;Yuhua Shi,&nbsp;Yunfei Lao,&nbsp;Yanling Ma,&nbsp;Jincheng Lou,&nbsp;Zuyang Zhang,&nbsp;Liru Fu,&nbsp;Yu Han,&nbsp;Junli Huo,&nbsp;Xiaobin Zhang,&nbsp;Yan Guo,&nbsp;Manhong Jia,&nbsp;Jian Li","doi":"10.1111/hiv.70033","DOIUrl":"10.1111/hiv.70033","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 <p>Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) infections are global public health concerns. Little research has been conducted on HCV incidence in people with HIV (PWH).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This was a retrospective cohort study to investigate HCV incidence and associated factors in PWH. HCV-negative PWH registered in national HIV databases were enrolled and followed up from 2004 to 2023. Cox proportional hazards models were utilized to identify factors associated with HCV infections.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>The study followed 50 245 HCV-negative PWH, totaling 272 979.3 person-years (PYs) of observation. We noted an HCV incidence rate of 0.70 per 100 PYs (95% confidence interval (CI) 0.67–0.73). Multivariate analysis indicated that being female (adjusted hazard ratio [aHR] 0.70), married (aHR 0.88), and those involved in homosexual intercourse (aHR 0.57) were associated with a lower risk of HCV infection. Conversely, an increased risk was found among those aged 20–39 years (aHR 2.97), 40–59 years (aHR 3.11), ≥ 60 years (aHR 1.80), treated at county-level antiretroviral therapy (ART) clinics (aHR 1.19), township-level ART clinics (aHR 1.83), those with a history of intravenous drug use (aHR 21.72), and individuals without CD4 testing (aHR 66.05) or HIV viral load testing (aHR 2.09). A 36% relative reduction in HCV transmission (aHR 0.64) was observed from 2010 to 2015, and a 29% relative reduction (aHR 0.71) was noted after 2016 compared with the pre-2010 levels.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>Despite the decrease in HCV incidence after 2010, achieving HCV elimination in PWH remains challenging. Future endeavours should prioritize improving HCV testing, intervention, and treatment in PWH.</p>\u0000 </section>\u0000 </div>","PeriodicalId":13176,"journal":{"name":"HIV Medicine","volume":"26 6","pages":"951-961"},"PeriodicalIF":2.8,"publicationDate":"2025-04-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144010630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}